Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vivet Therapeutics

- PMLiVE

Pfizer poaches cancer R&D head Jeff Settleman from Calico

Company gaining momentum in oncology

- PMLiVE

Oxford Biomedica gets £53m cash injection from Novo venture arm

Cell and gene therapy specialist needs to invest to stay ahead

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

- PMLiVE

Health comms agency emotive hires new cell and gene therapy leader

New division will cater to fast-expanding field

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Syncona launches another cell therapy company, Treg specialist Quell

Focuses on novel immune system approach

- PMLiVE

Bluebird and Alexion veterans launch cell and gene venture ElevateBio

'Basecamp' will provide expertise and labs to launch multiple firms

- PMLiVE

Pfizer’s alliance with Sosei Heptares bears first fruit

Partners focusing on GPCR-targeting drugs

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Speedy approval for Pfizer’s Onpattro rival

Approved in two different formulations

- PMLiVE

Gilead unveils plan to separate Kite cell therapy unit

Comes as Yescarta misses analyst expectations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links